Comparison between Bio Medica Laboratories IPO and Neochem Bio IPO.
Bio Medica Laboratories IPO is a SME Bookbuilding IPO proposed to list at NSE SME while Neochem Bio IPO is a SME Bookbuilding proposed to list at NSE SME.
| Bio Medica Laboratories IPO | Neochem Bio IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | NSE SME | NSE SME |
| Lead Managers | Narnolia Financial Services Ltd. | Vivro Financial Services Pvt.Ltd. |
| Registrar | Skyline Financial Services Pvt.Ltd. | MUFG Intime India Pvt.Ltd. |
| Market Maker | Rikhav Securities Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Bio Medica Laboratories IPO is up to ₹0.00 Cr whereas the issue size of the Neochem Bio IPO is up to ₹42.69 Cr. The final issue price of Bio Medica Laboratories IPO is and of Neochem Bio IPO is ₹98.00 per share.
| Bio Medica Laboratories IPO | Neochem Bio IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹93.00 per share | |
| Issue Price (Upper) | ₹98.00 per share | |
| Issue Price (Final) | ₹98.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1200 shares | |
| Fresh Issue Size | 32,05,200 shares | 43,56,000 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹42.69 Cr |
| OFS Issue Size | 3,76,800 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 35,82,000 shares | 43,56,000 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹42.69 Cr |
Bio Medica Laboratories IPO opens on , while Neochem Bio IPO opens on Dec 02, 2025. The closing date of Bio Medica Laboratories IPO and Neochem Bio IPO is , and Dec 04, 2025, respectively.
| Bio Medica Laboratories IPO | Neochem Bio IPO | |
|---|---|---|
| Anchor Bid Date | Dec 01, 2025 | |
| Issue Open | Dec 02, 2025 | |
| Issue Close | Dec 04, 2025 | |
| Basis Of Allotment (Tentative) | Dec 05, 2025 | |
| Initiation of Refunds (Tentative) | Dec 08, 2025 | |
| Credit of Share (Tentative) | Dec 08, 2025 | |
| Listing date (Tentative) | Dec 09, 2025 | |
| Anchor Lockin End date 1 | Jan 04, 2026 | |
| Anchor Lockin End date 2 | Mar 05, 2026 |
Bio Medica Laboratories IPO P/E ratio is , as compared to Neochem Bio IPO P/E ratio of 15.85.
| Bio Medica Laboratories IPO | Neochem Bio IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Bio Medica Laboratories Ltd.'s revenue increased by 150% and profit after tax (PAT) rose by 292% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)Neochem Bio Solutions Ltd.'s revenue increased by 39% and profit after tax (PAT) rose by 330% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 99.99 | 91.12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 66.7 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 15.85 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹167.78 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 99.59% | 48.82% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 48.20% | 41.67% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.02 | 1.80 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹6.18 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 99.59% | 48.82% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Bio Medica Laboratories IPO Retail Individual Investors (RII) are offered 0 shares while in Neochem Bio IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Bio Medica Laboratories IPO and 8,71,200 shares in Neochem Bio IPO.
| Bio Medica Laboratories IPO | Neochem Bio IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 13,03,200 shares |
| Market Maker Reservation | 1,89,600 shares | 2,32,800 shares |
| QIB | 0 shares | 8,71,200 shares |
| NII | 0 shares | 6,55,200 shares |
| RII | 0 shares | 15,26,400 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 43,56,000 shares |
Bio Medica Laboratories IPO subscribed in total, whereas Neochem Bio IPO subscribed 15.52x.
| Bio Medica Laboratories IPO | Neochem Bio IPO | |
|---|---|---|
| QIB (times) | 21.97x | |
| NII (times) | 21.15x | |
| Big NII (times) | 25.78x | |
| Small NII (times) | 11.88x | |
| RII (times) | 9.42x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 15.52x |
